Innovation | Novartis United States of America

Media Release
Apr 20, 2012
Novartis announces update to United States prescribing information for MS therapy Gilenya following FDA review
Media Release
Apr 03, 2012
Novartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand name
Media Release
Mar 19, 2012
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Media Release
Jan 25, 2012
Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
Media Release
Dec 13, 2011
Novartis Pivotal Study of Exjade® Shows Significant Reduction of Iron Overload in Patients with Non-transfusion-dependent Thalassemia
Media Release
Dec 12, 2011
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
Media Release
Nov 07, 2011
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Media Release
Sep 25, 2011
Novartis Drug Afinitor® Helps Women With Advanced Breast Cancer Live Significantly Longer Without Their Disease Progressing
Media Release
Sep 25, 2011
Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
Media Release
Sep 23, 2011
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Media Release
Sep 16, 2011
Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
Media Release
Aug 01, 2011
FDA approves supplemental new drug application for Novartis therapy Gilenya™ to include data showing reduction in T1 lesions in MS, a marker of disease activity

‹ Previous page
1
…
22
23
24
25
26
27
28
…
50
› Next page